If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Anemia

Peginesatide Requirements Do Not Differ By Race

May 13, 2012

NATIONAL HARBOR, Md.—Black hemodialysis (HD) patients with anemia require relatively more epoetin than their non-black counterparts to achieve similar hemoglobin (Hb) levels, but blacks and non-blacks required similar peginesatide doses, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
 

Rapid Anemia Management May Reduce Hospital Readmission Rates

May 12, 2012

NATIONAL HARBOR, Md.—Rapid anemia management (RAM) for patients with end-stage renal disease within seven days of hospital discharge decreases their rate of readmission, according to findings presented at the National Kidney Foundation 2012 Spring Clinical Meetings.
 

Complete Anemia Correction Better for Renal Transplant Patients

April 23, 2012

Completely correcting anemia in kidney transplant recipients may preserve kidney function better than partially correcting anemia.
 

With ESAs, Let Your Patient Be Your Guide: An Interview with Alan S. Kliger, MD

April 11, 2012

When using erythropoiesis-stimulating agents (ESAs) to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target and more on improving patient-perceived quality of life in such areas as fatigue, weakness, and shortness of breath, advises Alan S. Kliger, MD, Chief Medical Officer and Chief Quality Officer for the Saint Raphael Healthcare System in New Haven, Conn.
 

FDA Clears Once-Monthly Drug for Anemia in Dialysis Patients

March 27, 2012

The FDA has approved peginesatide (Omontys) for the treatment of anemia in adult dialysis patients.
 

Correcting Anemia Reduces Odds of Renal Transplant Failure

December 29, 2011

Complete correction of anemia (hemoglobin, 13 g/dL or higher) in kidney transplant recipients slows progression to chronic allograft nephropathy, a study found.
 

FDA Committee Favors Peginesatide

December 15, 2011

The FDA's Oncologic Drugs Advisory Committee, in a 15 to 1 vote, has agreed that peginesatide demonstrates a favorable benefit/risk profile for use in treatment of dialysis patients with anemia resulting from chronic kidney disease (CKD).
 

Novel Therapy for CKD Anemia Advances

November 16, 2011

PHILADELPHIA—A novel treatment for chronic kidney disease (CKD) patients with anemia is showing positive results following a Phase 1/2 clinical trial, according to findings reported at Kidney Week 2011.
 

Poor Response to ESAs Increases Death Risk in Hemodialysis Patients

September 07, 2011

Mortality in hemodialysis (HD) patients can be influenced by their responsiveness to erythropoiesis-stimulating agents (ESAs), according to Japanese researchers.
 

FDA Agrees to Review NDA for Peginesatide

July 27, 2011

The FDA has agreed to review a New Drug Application (NDA) for peginesatide for the treatment of anemia associated with chronic kidney disease (CKD) in adult dialysis patients, according to a joint announcement by the two companies colloraborating on the development of the drug.
 

FDA Recommend More Conservative Dosing of ESAs

July 13, 2011

The FDA is calling for more conservative dosing of erythropoiesis-stimulating agents (ESAs) when used to treat anemia in CKD patients due to the increased risks of cardiovascular events such as stroke, thrombosis, and death.
 

FDA Mulling Once-Monthly Anemia Drug

July 06, 2011

The FDA is reviewing a New Drug Application for peginesatide as a treatment for anemia associated with chronic renal failure in adult dialysis patients.
 

Post-Transplantation Anemia Risk Factors Identified

June 28, 2011

PRAGUE—Renal transplant recipients who have anemia three months after receiving a kidney are more likely to have anemia more than six months post-transplant, according to researchers.
 

Correcting Anemia Improves Fatigue in Dialysis Patients

April 30, 2011

LAS VEGAS—Correction of anemia with erythropoiesis-stimulated agents (ESAs) improves fatigue in dialysis patients compared with no treatment, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.
 

Oral Iron Found to Be the Optimal First Treatment

April 30, 2011

LAS VEGAS—Oral iron is the optimal first treatment strategy for most iron-deficient, anemic chronic kidney disease (CKD) patients not yet on dialysis, based on a recent analysis presented at the National Kidney Foundation's Spring Clinical Meetings.
 

Hyperphosphatemia and Anemia Risk Factors in Diabetic Nephropathy Patients

April 30, 2011

LAS VEGAS—Albumunuria, proteinuria, lower estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy are significantly associated with hyperphosphatemia and anemia, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.
 

Larger Doses of Maintenance IV Iron May Cut ESA Requirements

April 30, 2011

LAS VEGAS—Monthly requirements of erythropoiesis-stimulating agents (ESAs) to maintain target hemoglobin levels may be lower with larger doses of maintenance iron, according to data presented at the National Kidney Foundation's Spring Clinical Meetings.
 

Switch From Darbepoetin to Epoetin May Be Beneficial

April 29, 2011

LAS VEGAS—Switching anemic pre-dialysis chronic kidney disease (CKD) from darbepoetin to epoetin is associated with longer dosing intervals and lower drug costs, and hemoglobin levels are maintained in the recommended target range, according to a study presented at the National Kidney Foundation's Spring Clinical Meetings.
 

Transfusion Patterns Among ND-CKD Patients Characterized

April 29, 2011

LAS VEGAS—Blood transfusions are common for non-dialysis chronic kidney disease (ND-CKD) patients with persistent anemia, according to a report presented at the National Kidney Foundation's Spring Clinical Meetings.
 

Vitamin D Repletion May Reduce Darbepoetin Requirements

April 28, 2011

LAS VEGAS—Vitamin D repletion in patients with end-stage renal disease maintains hemoglobin (Hb) levels and results in decreased requirement of darbepoetin alfa, according to data presented at the National Kidney Foundation's Spring Clinical Meetings.
 

Iron Repletion Does Not Lower Platelet Counts

April 28, 2011

LAS VEGAS—Correction of iron deficiency does not significantly lower platelet counts in patients with chronic kidney disease (CKD), regardless of molecular weight or dose used, investigators reported at the National Kidney Foundation's Spring Clinical Meetings.
 

Dosing Intervals of Darbepoetin Alfa May Be Extended in Pre-Dialysis Patients

April 28, 2011

LAS VEGAS—Darbepoetin alfa dosing intervals in pre-dialysis patients with chronic kidney disease (CKD) may be extended beyond the approved one- or two-week frequency, researchers reported at the National Kidney Foundation's Spring Clinical Meetings.
 

Cinacalcet May Reduce ESA Use

February 23, 2011

PHOENIX—Cinacalcet hydrochloride (CH) treatment in dialysis patients with secondary hyperparathyroidism may improve responsiveness to an erythropoiesis-stimulating agent (ESA) by reducing systemic inflammation, resulting in decreased ESA requirements, new data suggest.
 

Low Vitamin D, Anemia Linked in CKD Patients

February 21, 2011

PHOENIX—Chronic kidney disease (CKD) patients with anemia have significantly lower levels of 25 vitamin D (25D) than those without anemia, researchers concluded.
 

Anemia Frequently Untreated in Non-Dialysis CKD Patients

November 20, 2010

A significant proportion of patients with CKD but not on dialysis (CKD-NOD) with new-onset moderately severe anemia do not receive treatment with iron or erythropoiesis-stimulating agents (ESAs), suggest study findings presented at Renal Week 2010 in Denver.
 

Predictive Ability of Hemoglobin Depends on Age, GFR

November 20, 2010

The ability of a given hemoglobin (Hb) level to predict mortality varies with both age and estimated glomerular filtration rate (eGFR), according to data shown at Renal Week 2010 in Denver.
 

Transfusions Linked to Worse Outcomes in Transplant Recipients

November 18, 2010

Blood transfusions increase the risk of adverse graft and patient outcomes in anemic renal transplant recipients, but treatment with erythropoiesis-stimulating agents (ESAs) do not, according to a study presented at Renal Week 2010 in Denver.
 

Transplant Anemia, Phosphorus Linked

November 18, 2010

Higher serum phosphorus levels are associated with lower blood hemoglobin (Hb) levels and a greater likelihood of anemia in renal transplant recipients, according to a study presented at Renal Week.
 

Epoetin May Be Renoprotective in Transplant Recipients

November 18, 2010

Renal transplant recipients who receive epoetin (EPO) treatment for post-transplant anemia may experience slower declines in kidney function, according to a study presented at Renal Week 2010 in Denver.
 

NAC May Treat Anemia in HD Patients, Study Shows

October 29, 2010

Oral N-acetylcysteine (NAC) supplementation may be a promising adjuvant treatment for uremic anemia and oxidative stress in hemodialysis (HD) patients, researchers say.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Overactive Bladder Prostate Cancer Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urinary Tract Infection Urology UTI

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions